

**E Tzagkaraki<sup>1#</sup>, A Batas<sup>1</sup>, I Anastasiou<sup>2</sup>, A Patrianakos<sup>2</sup>, F Parthenakis<sup>2</sup>, G Kochiadakis<sup>2</sup>, K Stratakis<sup>1</sup>, N Tavernarakis<sup>1</sup>, E Linardaki<sup>1\*</sup>**

<sup>1</sup>Diagnostic Genetics and Precision Medicine Unit, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology of Hellas, Heraklion 71003, Crete, Greece

<sup>2</sup>Cardiology Department, Heraklion University Hospital, Stavrakia, P.O. Box 1352, Heraklion, Crete, Greece

#Presenting author: Evmorfia Tzagkaraki, email: [evmorfia\\_tzagkaraki@imbb.forth.gr](mailto:evmorfia_tzagkaraki@imbb.forth.gr) \*Corresponding author: Emmanouela Linardaki, email: [emmanouela\\_linardaki@imbb.forth.gr](mailto:emmanouela_linardaki@imbb.forth.gr)

## Introduction


- ❖ Inherited Cardiac Disorders (CD) are a group of rare genetic diseases that constitute a major cause of sudden cardiac death and Heart Failure.
- ❖ Pathogenic mutations in genes encoding cardiac sarcomere proteins, cytoskeletal proteins and desmosomal proteins have been associated with Inherited Cardiac Disorders.
- ❖ The majority of these conditions are inherited in an autosomal dominant manner.
- ❖ The island of Crete may exhibit mutational hotspot patterns due to its relative geographical "isolation".

## Aim

- ❖ Establish a genetic diagnosis in patients with CD from Crete.
- ❖ Determine the diagnostic yield and genetic diversity of CD cohorts.
- ❖ Confirm a clinical diagnosis in relatives or identify asymptomatic relatives who are at risk.

## Methods

- ❖ 48 index patients (proband) (21 HCM, 18 DCM/HNDC, 2 ACM, 3 Channelopathies, 1 HCM/ACM overlap phenotype, 1 mild DCM features that suffered aborted SCD likely attributed to drug-induced QT-interval prolongation, as well as 2 SCD).
- ❖ genomic DNA analyzed using NGS panel *Extended Cardio Solution* by Sophia Genetics™ (complete coding sequence of 128 clinically relevant genes).
- ❖ Bioinformatics analysis: *SophiaDDM™* platform (Sophia Genetics™).
- ❖ Clinical curation according to the American College of Medical Genetics and Genomics (ACMG) criteria [1].
- ❖ Pathogenic (P) and/or Likely Pathogenic (LP) variants verified by Sanger Sequencing.
- ❖ Family studies: 84 first, second and third degree relatives of P/LP positive probands screened with Sanger sequencing.
- ❖ Cascade screening included relatives of 7 P/LP positive probands (3 AC, 2 ATTR-CM, 1 Channelopathy and 1 HCM) that had been previously genotyped elsewhere.




### Disease distribution in the proband group


HCM: Hypertrophic Cardiomyopathy  
DCM: Dilated Cardiomyopathy  
ACM: Arrhythmogenic Cardiomyopathy  
SCD: Sudden Cardiac Death  
SCD prev.: SCD prevented  
HNDC: Hypertrophic non-dilated CM.

## Results


**A) Overall Genetic Diagnostic Yield:** The genetic analysis revealed a P/LP mutation in 26/48 probands (54%) with CD.




**B) HCM genetic diagnostic yield** was 76%. Most frequently mutated genes: MYBPC3 (38%) and MYH7 (33%), in line with international literature.



**C) DCM/HNDC genetic diagnostic yield** was 39%. Most frequently mutated gene: TTN (22%).




- ❖ Ten probands carried P/LP variants that had not been previously reported in the literature.
- ❖ A **novel LP variant** in gene **MYBPC3** (NM\_000256: c.3784\_3795del (p.A1262\_E1265del)) was identified in 6/17 gene positive HCM probands of proximal geographic origin (4 unrelated and 2 half siblings), indicating a mutational hotspot in Crete and a possible founder effect of this variant in the Cretan population.
- ❖ Seven more unrelated HCM probands carried the **known LP variant MYH7** - NM\_000257:c.1063G>A (p.A355T), suggestive of a second mutational hotspot.



### Mutational hotspots of HCM in Crete

- MYBPC3, NM\_000256:c.3784\_3795del (p.A1262\_E1265del) - novel variant
- MYH7 - NM\_000257:c.1063G>A (p.A355T) - known variant



### Family Cascade Screening:

40/84 family members (48%) tested positive for the family mutation  
44/84 tested negative (52%). All 44 gene - negative family members are healthy individuals (Gene Negative-Phenotype negative)  
27 out of the 40 positive family members, are healthy asymptomatic individuals with a genetic finding associated with the inherited cardiac disease (Gene Positive-Phenotype Negative, 32%).  
All Phenotype Positive members are also Gene Positive (16%).

- ❖ In 2 families with SCD we identified the genetic cause in the deceased probands; family cascade screening in one of these families, revealed the pathogenic variant in one of the two healthy daughters of the proband.

## Discussion

- ❖ Crete has always been a natural terrain of rare inherited diseases due to its natural geographical isolation, which may promote the emergence of Inherited Cardiac Disorders.
- ❖ **Genetic Diagnosis was established in 54%** of tested probands using the 128 gene NGS panel.
- ❖ Our studies revealed **2 mutational hotspots in HCM**, one of which involved a previously unreported MYBPC3 mutation.
- ❖ Family Cascade screening revealed the presence of a P/LP variant in 27 healthy asymptomatic individuals, highlighting the **importance of family genetic screening in early diagnosis and clinical intervention.**

## Acknowledgments

This work was funded by the National Network of Precision Medicine in Cardiology and Prevention of SCD in the Young, in the framework of Work Package 1 (Hellenic Research Network for the Genetics of Human Cardiovascular Disease and the Prevention of Sudden Juvenile Death - Hellenic Precision Medicine Research Network for Neurodegenerative Diseases), of the project "Infrastructures for National Research Networks for Precision Medicine and Climate Change" no. 2018ΣΕ01300001 of the GSRT National Public Investments Program.

## References

[1] Richards, S., et al (2015). Genetics in Medicine 17, 405-423